The National Health Surveillance Agency (Anvisa) informed, this Friday (3), about the publication of a letter to health professionals from the company Eli Lilly do Brasil about the inclusion of new data in the package insert of the drug Olumiant (baricitinib), against to Covid-19.
The change in the package insert adds a warning for possible Major Adverse Cardiovascular Events (MACE) and updates on the occurrence of venous thromboembolism and cancer, including lymphoma.
According to Anvisa, adverse events were identified from a clinical study and a retrospective cohort, which evaluated patients being treated for rheumatoid arthritis.
In a note, Anvisa said that the data should be considered before prescribing, being recommended to assess the benefits and risks of treatment with baricitinib for each patient.
Reference: CNN Brasil
